Arylcyclohexylamine

Arylcyclohexylamine

Phencyclidine, the prototypal arylcyclohexylamine derivative.

Arylcyclohexylamines, also known as arylcyclohexamines or arylcyclohexanamines, are a chemical class of pharmaceutical, designer, and experimental drugs.

Contents

  • History 1
  • Structure 2
  • Pharmacology 3
  • List of arylcyclohexylamines 4
  • Kalir 5
  • Ahmadi 6
  • Rigid 7
  • References 8
  • External links 9

History

Phencyclidine (PCP) is believed to be the first arylcyclohexylamine with recognized anesthetic properties, but several arylcyclohexylamines were described before PCP in the scientific literature, beginning with PCA (1-phenylcyclohexan-1-amine) the synthesis of which was first published in 1907. PCE was reported in 1953 and PCMo in 1954, with the latter compound described as a potent sedative.[1] Arylcyclohexylamines anesthetics were intensively investigated at Parke-Davis, beginning with the 1956 synthesis of phencyclidine and later the related compound ketamine.[1] The 1970s saw the debut of these compounds, especially PCP and its analogues, as illicitly used recreational drugs due to their dissociative hallucinogenic and euphoriant effects. Since, the class has been expanded by scientific research into stimulant, analgesic, and neuroprotective agents, and also by clandestine chemists in search of novel recreational drugs.

Structure

An arylcyclohexylamine is composed of a cyclohexylamine unit with an aryl moiety attachment. The aryl group is positioned geminal to the amine. In the simplest cases, the aryl moiety is typically a phenyl ring, sometimes with additional substitution. The amine is usually not primary, secondary amines such as methylamino or ethylamino, or tertiary cycloalkylamines such as piperidino and pyrrolidino, are the most commonly encountered N-substituents.

General structure of arylcyclohexylamines

Pharmacology

Arylcyclohexylamines varyingly possess NMDA receptor antagonistic,[2][3] dopamine reuptake inhibitory,[4] and μ-opioid receptor agonistic[5] properties. Additionally, σ receptor agonistic,[6] nACh receptor antagonistic,[7] and D2 receptor agonistic[8] actions have been reported for some of these agents. Antagonism of the NMDA receptor confers anesthetic, anticonvulsant, neuroprotective, and dissociative effects; blockade of the dopamine transporter mediates stimulant and euphoriant effects as well as psychosis in high amounts; and activation of the μ-opioid receptor causes analgesic and euphoriant effects. Stimulation of the σ and D2 receptors may also contribute to hallucinogenic and psychomimetic effects.[8]

Versatile agents with a wide range of possible pharmacological activities depending on the extent and range to which chemical modifications are implemented. The various choice of substitutions that are made allows for "fine-tuning" of the pharmacological profile that results. As examples, BTCP is a selective dopamine reuptake inhibitor,[4] PCP is primarily an NMDA antagonist,[2] and BDPC is a superpotent μ-opioid agonist,[9] while PRE-084 is a selective sigma receptor agonist.[10] Thus, radically different pharmacology is possible through different structural combinations.

List of arylcyclohexylamines

Compound Aryl Substituent N Group Cyclohexyl ring
PCA[11] Phenyl NH2 -
PCM[11] Phenyl Methylamino -
Eticyclidine Phenyl Ethylamino -
PCPr[12] Phenyl n-Propylamino -
PCiP Phenyl Isopropylamino -
PCBu Phenyl n-Butylamino -
PCEOH Phenyl Hydroxyethylamino -
PCMEA[13] Phenyl Methoxyethylamino -
PCEEA Phenyl Ethoxyethylamino -
PCMPA Phenyl Methoxypropylamino -
PCDM[11] Phenyl Dimethylamino -
Dieticyclidine Phenyl Diethylamino -
2-HO-PCP[14] Phenyl Piperidine 2-Hydroxy
2-Me-PCP[15] Phenyl Piperidine 2-Methyl
2-MeO-PCP[16] Phenyl Piperidine 2-Methoxy
2-Keto-PCP Phenyl Piperidine 2-Keto
2-Keto-PCE Phenyl Ethylamino 2-Keto
4-Methyl-PCP Phenyl Piperidine 4-Methyl
4-Keto-PCP Phenyl Piperidine 4-Keto
2-Cl-PCP o-Chlorophenyl Piperidine -
2-MeO-PCP o-Methoxyphenyl Piperidine -
3-F-PCP[17] m-Fluorophenyl Piperidine -
3-Me-PCP[18] m-Methylphenyl Piperidine -
3-NH2-PCP m-Aminophenyl Piperidine -
3-HO-PCP m-Hydroxyphenyl Piperidine -
3-MeO-PCP m-Methoxyphenyl Piperidine -
3-MeO-PCE m-Methoxyphenyl Ethylamino -
3-MeO-PCPr m-Methoxyphenyl n-Propylamino -
3-MeO-PCPy[19] m-Methoxyphenyl Pyrrolidine -
4-HO-PCP p-Hydroxyphenyl Piperidine -
Methoxydine (4-MeO-PCP) p-Methoxyphenyl Piperidine -
p-F-PCP[17] p-Fluorophenyl Piperidine -
Arketamine o-Chlorophenyl Methylamino 2-Keto
Deschloroketamine Phenyl Methylamino 2-Keto
Esketamine o-Chlorophenyl Methylamino 2-Keto
Ethketamine o-Chlorophenyl Ethylamino 2-Keto
Ketamine o-Chlorophenyl Methylamino 2-Keto
Methoxyketamine o-Methoxyphenyl Methylamino 2-Keto
Fluoroketamine o-Fluorophenyl Methylamino 2-Keto
Bromoketamine o-Bromophenyl Methylamino 2-Keto
Methoxetamine m-Methoxyphenyl Ethylamino 2-Keto
Methoxmetamine m-Methoxyphenyl Methylamino 2-Keto
Phencyclidine (PCP) Phenyl Piperidine -
PC3MP Phenyl 3-Methylpiperidine -
PC4MP Phenyl 4-Methylpiperidine -
Rolicyclidine (PCPy) Phenyl Pyrrolidine -
PCDMPy Phenyl 3,3-Dimethylpyrrolidine -
PCMo Phenyl Morpholine -
DPD DiPhenyl Ethylpiperidine -
Methoxy-PCM[3] o-Methoxyphenyl Morpholine -
Methyl-PCM[20] p-Methylphenyl Morpholine -
Hydroxy-methyl-PCM 2-Methyl-4-hydroxyphenyl Morpholine -
TCM 2-Thienyl Methylamino -
TCE 2-Thienyl Ethylamino -
Tenocyclidine (TCP) 2-Thienyl (Furan?) Piperidine -
TCPy 2-Thienyl Pyrrolidine -
Tiletamine 2-Thienyl Ethylamino 2-Keto
Gacyclidine 2-Thienyl Piperidine 2-Methyl
BDPC p-Bromophenyl Dimethylamino 4-Phenethyl-4-hydroxy
Dimetamine p-Methylphenyl Dimethylamino 4-Keto
BTCP[21] Benzothiophen-2-yl Piperidine -
PRE-084 Phenyl Morpholinylethylcarboxylate -
  • Other cycloalkane ring sizes have been experimented with than just purely thinking in terms of the cyclohexylamine. The requisite cycloalkylketone is reacted with PhMgBr; 3° alcohol is then reacted with NaN3; azide then reduced with LAH. Then in the final step the piperidine ring is constructed with 1-5-dibromo-pentane.[22]

In the p- and m-fluoro pcp analog paper, pyrrolidino ring sizes were also experimented with.

Kalir

Asher Kalir Pcp analgesic analog (1981).[23]

Ahmadi

Ahmadi 1-tetralone (2010).[24] Ahmadi (2010).[25] Ahmadi (2014).[26] Ahmadi pcp (2010).[27]
Ahmadi (2009).[28] Ahmadi (2011).[29]
Ahmadi pcp Maze (2012).[30] F, L, B, P.
Ketamine Ahmadi (2012).[31]

Rigid

Conformationally contrained analogs have also been prepared and researched by Morieti et al.[32]

References

  1. ^ a b Morris, H.; Wallach, J. (2014). "From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs". Drug Testing and Analysis 6 (7-8): 614–32.  
  2. ^ a b Ahmadi, A.; Mahmoudi, A. (2005). "Synthesis and biological properties of 2-hydroxy-1-(1-phenyltetralyl)piperidine and some of its intermediates as derivatives of phencyclidine". Arzneimittel-Forschung 55 (9): 528–532.  
  3. ^ a b Ahmadi, A.; Khalili, M.; Hajikhani, R.; Naserbakht, M. (2011). "New morpholine analogues of phencyclidine: Chemical synthesis and pain perception in rats". Pharmacology Biochemistry and Behavior 98 (2): 227–233.  
  4. ^ a b Chaudieu, I.; Vignon; Chicheportiche; Kamenka; Trouiller; Chicheportiche (1989). "Role of the aromatic group in the inhibition of phencyclidine binding and dopamine uptake by PCP analogs". Pharmacology, Biochemistry, and Behavior 32 (3): 699–705.  
  5. ^ Itzhak, Y.; Simon (1984). "A novel phencyclidine analog interacts selectively with mu opioid receptors". The Journal of Pharmacology and Experimental Therapeutics 230 (2): 383–386.  
  6. ^ He, X. S.; Raymon, L. P.; Mattson, M. V.; Eldefrawi, M. E.; De Costa, B. R. (1993). "Synthesis and biological evaluation of 1-1-(2-benzobthienyl)cyclohexylpiperidine homologues at dopamine-uptake and phencyclidine- and sigma-binding sites". Journal of Medical Chemistry 36 (9): 1188–1193.  
  7. ^ Eterović, V. A.; Lu, R.; Eakin, A. E.; Rodríguez, A. D.; Ferchmin, P. A. (1999). "Determinants of phencyclidine potency on the nicotinic acetylcholine receptors from muscle and electric organ". Cellular and molecular neurobiology 19 (6): 745–757.  
  8. ^ a b Seeman, P.; Ko, F.; Tallerico, T. (2005). "Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics". Molecular Psychiatry 10 (9): 877–883.  
  9. ^ Lednicer, D.; Vonvoigtlander, P. F. (1979). "4-(p-Bromophenyl)-4-(dimethylamino)-1-phenethylcyclohexanol, an extremely potent representative of a new analgesic series".  
  10. ^ Maurice, T.; Su, T. P.; Parish, D. W.; Nabeshima, T.; Privat, A. (1994). "PRE-084, a sigma selective PCP derivative, attenuates MK-801-induced impairment of learning in mice". Pharmacology, Biochemistry, and Behavior 49 (4): 859–869.  
  11. ^ a b c Thurkauf, A.; De Costa, B.; Yamaguchi, S.; Mattson, M. V.; Jacobson, A. E.; Rice, K. C.; Rogawski, M. A. (1990). "Synthesis and anticonvulsant activity of 1-phenylcyclohexylamine analogs". Journal of Medicinal Chemistry 33 (5): 1452.  
  12. ^ Sauer, C.; Peters, F.; Staack, R.; Fritschi, G.; Maurer, H. (2008). "Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatography-mass spectrometry". Journal of Chromatography A 1186 (1–2): 380–390.  
  13. ^ Sauer, C.; Peters, F.; Schwaninger, A.; Meyer, M.; Maurer, H. (2009). "Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine". Biochemical pharmacology 77 (3): 444–450.  
  14. ^ Ahmadi, A.; Mahmoudi, A. (2005). "Synthesis and biological properties of 2-hydroxy-1-(1-phenyltetralyl)piperidine and some of its intermediates as derivatives of phencyclidine". Arzneimittel-Forschung 55 (9): 528–532.  
  15. ^ Iorio, M. A.; Tomassini, L.; Mattson, M. V.; George, C.; Jacobson, A. E. (1991). "Synthesis, stereochemistry, and biological activity of the 1-(1-phenyl-2-methylcyclohexyl)piperidines and the 1-(1-phenyl-4-methylcyclohexyl)piperidines. Absolute configuration of the potent trans-(-)-1-(1-phenyl-2-methylcyclohexyl)piperidine".  
  16. ^ Ahmadi, A.; Mahmoudi, A. (2006). "Synthesis with improved yield and study on the analgesic effect of 2-methoxyphencyclidine".  
  17. ^ a b Ogunbadeniyi, A. M.; Adejare, A. (2002). "Syntheses of fluorinated phencyclidine analogs". Journal of Fluorine Chemistry 114: 39.  
  18. ^ Wallach, J.; Paoli, G. D.; Adejare, A.; Brandt, S. D. (2013). "Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues". Drug Testing and Analysis 6 (7–8): 633–50.  
  19. ^ Wallach, J.; Paoli, G. D.; Adejare, A.; Brandt, S. D. (2013). "Preparation and analytical characterization of 1-(1-phenylcyclohexyl)piperidine (PCP) and 1-(1-phenylcyclohexyl)pyrrolidine (PCPy) analogues". Drug Testing and Analysis 6 (7–8): 633–50.  
  20. ^ Ahmadi A, Khalili M, Hajikhani R, Naserbakht M (2011). "Synthesis and determination of acute and chronic pain activities of 1-[1-(4-methylphenyl) (cyclohexyl)] morpholine as a new phencyclidine derivative in rats". Arzneimittel-Forschung 61 (2): 92–7.  
  21. ^ Vignon, J.; Pinet, V.; Cerruti, C.; Kamenka, J. M.; Chicheportiche, R. (1988). "3HN-1-(2-benzo(b)thiophenyl)cyclohexylpiperidine (3HBTCP): A new phencyclidine analog selective for the dopamine uptake complex". European Journal of Pharmacology 148 (3): 427–436.  
  22. ^ McQuinn, Roy L. (1981). "Structure-activity relationships of the cycloalkyl ring of phencyclidine". Journal of Medicinal Chemistry 24 (12): 1429–1432.  
  23. ^ Itzhak, Y. (1981). "New analgesic drugs derived from phencyclidine". Journal of Medicinal Chemistry 24 (5): 496–9.  
  24. ^ Ahmadi, A; Khalili; Hajikhani; Barghi; Mihandoust (2010). "Synthesis and determination of chronic and acute thermal and chemical pain activities of a new derivative of phencyclidine in rats". Iranian journal of pharmaceutical research : IJPR 9 (4): 379–85.  
  25. ^ Ahmadi, A; Khalili, M; Mihandoust, F; Barghi, L (2010). "Synthesis and determination of acute and chronic pain activities of 1-1-(3-methylphenyl) (tetralyl)piperidine as a new derivative of phencyclidine via tail immersion and formalin tests". Arzneimittel-Forschung 60 (1): 30–5.  
  26. ^ Ahmadi, A; Khalili, M; Marami, S; Ghadiri, A; Nahri-Niknafs, B (2014). "Synthesis and pain perception of new analogues of phencyclidine in NMRI male mice". Mini reviews in medicinal chemistry 14 (1): 64–71.  
  27. ^ Ahmadi, A; Solati, J; Hajikhani, R; Onagh, M; Javadi, M (2010). "Synthesis and analgesic effects of 1-1-(2-methylphenyl)(cyclohexyl)-3-piperidinol as a new derivative of phencyclidine in mice". Arzneimittel-Forschung 60 (8): 492–6.  
  28. ^ Ahmadi, A; Khalili, M; Abbassi, S; Javadi, M; Mahmoudi, A; Hajikhani, R (2009). "Synthesis and study on analgesic effects of 1-1-(4-methylphenyl) (cyclohexyl) 4-piperidinol and 1-1-(4-methoxyphenyl) (cyclohexyl) 4-piperidinol as two new phencyclidine derivatives". Arzneimittel-Forschung 59 (4): 202–6.  
  29. ^ Ahmadi, A; Solati, J; Hajikhani, R; Pakzad, S (2011). "Synthesis and analgesic effects of new pyrrole derivatives of phencyclidine in mice". Arzneimittel-Forschung 61 (5): 296–300.  
  30. ^ Hajikhani, R; Ahmadi, A; Naderi, N; Yaghoobi, K; Shirazizand, Z; Rezaee, N. M.; Niknafs, B. N. (2012). "Effect of phencyclidine derivatives on anxiety-like behavior using an elevated-plus maze test in mice". Advances in clinical and experimental medicine : official organ Wroclaw Medical University 21 (3): 307–12.  
  31. ^ Ahmadi, A; Khalili, M; Hajikhani, R; Hosseini, H; Afshin, N; Nahri-Niknafs, B (2012). "Synthesis and study the analgesic effects of new analogues of ketamine on female wistar rats". Medicinal chemistry (Shariqah (United Arab Emirates)) 8 (2): 246–51.  
  32. ^ Moriarty, R.; Enache, L.; Zhao, L.; Gilardi, R.; Mattson, M.; Prakash, O. (1998). "Rigid phencyclidine analogues. Binding to the phencyclidine and sigma 1 receptors". Journal of Medical Chemistry 41 (4): 468–477.  

External links

  • From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs
  • Synthesis and Effects of PCP Analogs
  • Interview with an Arylcyclohexylamine Chemist
  • PCP analogs (Cumulative)